These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 22368156)

  • 1. Clinicopathologic study and outcome analysis of thyroid lymphomas: experience from a tertiary cancer center.
    Katna R; Shet T; Sengar M; Menon H; Laskar S; Prabhash K; D'Cruz A; Nair R
    Head Neck; 2013 Feb; 35(2):165-71. PubMed ID: 22368156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma.
    Sagaert X; de Paepe P; Libbrecht L; Vanhentenrijk V; Verhoef G; Thomas J; Wlodarska I; De Wolf-Peeters C
    J Clin Oncol; 2006 Jun; 24(16):2490-7. PubMed ID: 16636337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non-germinal centre phenotype, independent of gains and structural aberrations at 3p14.1.
    Hoeller S; Schneider A; Haralambieva E; Dirnhofer S; Tzankov A
    Histopathology; 2010 Jul; 57(1):73-80. PubMed ID: 20579129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
    Nyman H; Jerkeman M; Karjalainen-Lindsberg ML; Banham AH; Enblad G; Leppä S
    Eur J Haematol; 2009 May; 82(5):364-72. PubMed ID: 19141121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New prognostic relevant factors in primary cutaneous diffuse large B-cell lymphomas.
    Hallermann C; Niermann C; Fischer RJ; Schulze HJ
    J Am Acad Dermatol; 2007 Apr; 56(4):588-97. PubMed ID: 17289214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma.
    Banham AH; Connors JM; Brown PJ; Cordell JL; Ott G; Sreenivasan G; Farinha P; Horsman DE; Gascoyne RD
    Clin Cancer Res; 2005 Feb; 11(3):1065-72. PubMed ID: 15709173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
    Thieblemont C; Briere J; Mounier N; Voelker HU; Cuccuini W; Hirchaud E; Rosenwald A; Jack A; Sundstrom C; Cogliatti S; Trougouboff P; Boudova L; Ysebaert L; Soulier J; Chevalier C; Bron D; Schmitz N; Gaulard P; Houlgatte R; Gisselbrecht C
    J Clin Oncol; 2011 Nov; 29(31):4079-87. PubMed ID: 21947824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Both FOXP1 and p65 expression are adverse risk factors in diffuse large B-cell lymphoma: a retrospective study in China.
    Hu CR; Wang JH; Wang R; Sun Q; Chen LB
    Acta Histochem; 2013 Mar; 115(2):137-43. PubMed ID: 22809882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preferential expression of truncated isoforms of FOXP1 in primary central nervous system lymphoma.
    Courts C; Brunn A; Montesinos-Rongen M; Siemer D; Hans V; Paulus W; Wiestler OD; Küppers R; Siebert R; Deckert M
    J Neuropathol Exp Neurol; 2009 Sep; 68(9):972-6. PubMed ID: 19680146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastric and intestinal diffuse large B-cell lymphomas are clinically and immunophenotypically different. An immunohistochemical and clinical study.
    Connor J; Ashton-Key M
    Histopathology; 2007 Nov; 51(5):697-703. PubMed ID: 17927592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary testicular diffuse large B-cell lymphoma shows an activated B-cell-like phenotype.
    Li D; Xie P; Mi C
    Pathol Res Pract; 2010 Sep; 206(9):611-5. PubMed ID: 20627604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diffuse large B-cell lymphoma of the orbit: clinicopathologic, immunohistochemical, and prognostic features of 20 cases.
    Stacy RC; Jakobiec FA; Herwig MC; Schoenfield L; Singh A; Grossniklaus HE
    Am J Ophthalmol; 2012 Jul; 154(1):87-98.e1. PubMed ID: 22503694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome.
    Larouche JF; Berger F; Chassagne-Clément C; Ffrench M; Callet-Bauchu E; Sebban C; Ghesquières H; Broussais-Guillaumot F; Salles G; Coiffier B
    J Clin Oncol; 2010 Apr; 28(12):2094-100. PubMed ID: 20308668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOXP1 expression and its clinicopathologic significance in nodal and extranodal diffuse large B-cell lymphoma.
    Yu B; Zhou X; Li B; Xiao X; Yan S; Shi D
    Ann Hematol; 2011 Jun; 90(6):701-8. PubMed ID: 21120478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary lymphoma of bone: extranodal lymphoma with favourable survival independent of germinal centre, post-germinal centre or indeterminate phenotype.
    Heyning FH; Hogendoorn PC; Kramer MH; Holland CT; Dreef E; Jansen PM
    J Clin Pathol; 2009 Sep; 62(9):820-4. PubMed ID: 19734480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary diffuse large B-cell lymphomas of the bone: prognostic relevance of protein expression and clinical factors.
    Adams H; Tzankov A; d'Hondt S; Jundt G; Dirnhofer S; Went P
    Hum Pathol; 2008 Sep; 39(9):1323-30. PubMed ID: 18614198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma.
    Tzankov A; Meier C; Hirschmann P; Went P; Pileri SA; Dirnhofer S
    Haematologica; 2008 Feb; 93(2):193-200. PubMed ID: 18223287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.
    Copie-Bergman C; Gaulard P; Leroy K; Briere J; Baia M; Jais JP; Salles GA; Berger F; Haioun C; Tilly H; Emile JF; Banham AH; Mounier N; Gisselbrecht C; Feugier P; Coiffier B; Molina TJ
    J Clin Oncol; 2009 Nov; 27(33):5573-9. PubMed ID: 19786664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study.
    Linderoth J; Jerkeman M; Cavallin-Ståhl E; Kvaløy S; Torlakovic E;
    Clin Cancer Res; 2003 Feb; 9(2):722-8. PubMed ID: 12576441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD10 and Bcl-2 expression combined with the International Prognostic Index can identify subgroups of patients with diffuse large-cell lymphoma with very good or very poor prognoses.
    Biasoli I; Morais JC; Scheliga A; Milito CB; Romano S; Land M; Pulcheri W; Spector N
    Histopathology; 2005 Mar; 46(3):328-33. PubMed ID: 15720419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.